Overactive bladder symptoms in women: Current concepts in patient management

Canadian Journal of Urology

Volumn 17, Issue , 2010, Pages 12-17

  Easton, William A ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

Antimuscarinic agents; Detrusor overactivity; Overactive bladder; Urinary incontinence

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT;

AGE DISTRIBUTION; AGED; FEMALE; HOSPITALIZATION; HUMAN; INCIDENCE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; OVERACTIVE BLADDER; PATIENT CARE; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; STANDARD; STRESS INCONTINENCE; SUBURETHRAL SLING; TREATMENT OUTCOME; URODYNAMICS;

AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INCIDENCE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PATIENT CARE; PROGNOSIS; QUALITY OF LIFE; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SUBURETHRAL SLINGS; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE, STRESS; URODYNAMICS;

EID: 77952472674     PISSN: 11959479     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Haab F. Drug evaluation. Women's Health 2005;1(3):331-343.
2. Abrams P, Cardozo L, Fall M, Griffiths D, Ulmsten U, van Kerrebroeck P, Victor A, Wein A. The standardization of terminology of lower urinary tract function: report from the Standardization Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21(2):167-178.
3. Brown JS, Vitinghoff E, Wyman JF, Stone KL, Nevitt MC, Ensrud KE, Grady D. Urinary incontinence: does it increase risk for falls and fractures? Study of Osteoporotic Fractures Research Group.J Am Geriatr Soc 2000;48(7):721-725.
4. Zorn BH, Montgomery H, Pieper K, Gray M, Steers WD. Urinary incontinence and depression. J Urol 1999;162(1):82-84.
5. Vigod SN, Stewart DE. Major depression in female urinary incontinence. Psychosomatics 2006;47(2):147-151.
6. Davila GW, Nelmark M. The overactive bladder: prevalence and effects on quality of life. Clin Obstet Gynecol 2002;45(1):173-181.
7. Thompson JF. Geriatric urological disorders. In: Koda- KimbleMA, Young LY editors. Applied Therapeutics :The Clinical Use of Drugs. Baltimore: Lippincott Williams & Wilkins;2005:101:24-101:29.
8. Fall M. Electrical pelvic fl oor stimulation for the control of detrusor instability Neurourol Urodyn 4 (4):329-335.
9. Abrams P, Artibani W, Cardozo L, in Clinical Manual of Incontinence in Women 2005, Health Publications.
10. Herschorn S, Pommerville P, Stothers S et al. Tolerability of solifenacin in comparison with oxybutynin immediate release in patients overactive bladder: results of the VECTOR Study. Late Breaking Science Foru, AUA Annual Meeting 2009, Chicago, Illinois, USA.
11. Herschorn S et al. Tolerability of solifenacin in comparison to oxybutynin immediate release in elderly patients with overactive bladder: sub-analysis of results from the VECTOR study.International Uro-Gynecology Association meeting: April 2009.
12. Terry AV, Buccafusco JJ. The cholinergic hypothesis of age and Alzheimer's disease-related cognitive defi cits: Recent challenges and their implications for novel drug development. J Pharm and Exp Ther 2003;306(3):821-827.
13. Kay GG, Abou-Donia MB, Messer S,Murphy DG, Tsao JW, Ouslander JG. Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients. J Am Geriatr Soc 2005;53(12):2195-2201.
14. Kay, GG, Crook T, Rekeda L, Lima R, Ebinger U, Arguinzoniz M, Steel M. Differential effects of the antimuscarinic agents darifenacin and oxybutynin ER on memory in older subjects.Eur Urol 2006;50(2):317-326.
15. Anderson RU, MacDiarmid S, Kell S, Barada JH, Serels S, Goldberg RP. Effectiveness and tolerability of extended-release oxybutynin vs extended-release tolterodine in women with or without prior anticholinergic treatment for overactive bladder.Int Urogynecol J Pelvic Floor Dysfunct 2006;17(5):502-511. Epub 2006 May 3.
16. FDA prescribing guidelines 2009.Available at: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm175916.htm Accessed January 30, 2010.
17. Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer.Climacteric 2003;6(1):45-52.